^
Association details:
| Biomarker: | ARID1A mutation + MSI-H |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report
Published date:
02/19/2021
Excerpt:
Liquid biopsy test reported actionable alterations in ARID1A gene...The patient was treated with immunotherapy, and showed a treatment response lasting for 19 months until a new metastasis appeared at the right deltoid muscle. Genomic analysis of a sample of this metastasis confirmed PD-L1 positivity of greater than 50% with CD8+ T cells expression and showed MSI with a deleterious c.298C>T (p.R100*) MLH1 gene mutation.
Secondary therapy:
vinorelbine tartrate
DOI:
10.1186/s13256-020-02589-1
